Compugen Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>CO</div>
CGEN -- USA Stock  

USD 16.30  1.35  7.65%

As many investors are getting excited about healthcare space, Compugen and NantKwest may be going in opposite directions. We are going to inspect some of the competitive aspects of both Compugen and NantKwest.
Published over a month ago
View all stories for Compugen | View All Stories
Will Compugen (NASDAQ:CGEN) institutional investors shift to NantKwest (NASDAQ:NK)?
By analyzing existing basic indicators between Compugen and NantKwest, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in NantKwest with a short position in Compugen. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Compugen has an asset utilization ratio of 10.1 percent. This suggests that the company is making $0.1 for each dollar of assets. An increasing asset utilization means that Compugen is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Compugen or NantKwest is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Compugen's Liquidity

Compugen financial leverage refers to using borrowed capital as a funding source to finance Compugen ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Compugen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Compugen's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Compugen, but it might be worth checking our own buy vs. sell analysis

Correlation Between Compugen and NantKwest

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Compugen together with similar or unrelated positions with a negative correlation. For example, you can also add NantKwest to your portfolio. If NantKwest is not perfectly correlated to Compugen it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Compugen for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between CGEN and NK for more information.

Note

Are you currently holding both Compugen and NantKwest in your portfolio? Please note if you are using this as a pair-trade strategy between Compugen and NantKwest, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Detailed Outlook On Compugen

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Compugen revenue. Based on the latest financial disclosure, Compugen reported 7.8 M of revenue. This is 99.9% lower than that of the Healthcare sector and 98.95% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.92% higher than that of Compugen. As for NantKwest we see revenue of 59 K, which is 99.99% lower than that of the Biotechnology

Sector
742.9 M
CGEN7.8 Million1.04
Sector742.91 Million98.95
NK59,0000.007859

Compugen has a good chance to finish above $14.57 in 2 months

Latest kurtosis is at 1.83. Compugen is displaying above-average volatility over the selected time horizon. Investors should scrutinize Compugen independently to ensure intended market timing strategies are aligned with expectations about Compugen volatility.

Our Takeaway on Compugen Investment

Whereas other companies in the biotechnology industry are either recovering or due for a correction, Compugen may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 30th of July 2020, our research shows that Compugen is a rather somewhat reliable investment opportunity with a average probability of bankruptcy in the next two years. From a slightly different view, the entity currently appears to be undervalued. However, our latest 30 days advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Compugen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com